Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Discovery of noncovalent peptidomimetic proteasome inhibitors for the treatment of MM

April 7, 2022

New SPNS2 inhibitors synthesized by University of Virginia

April 6, 2022

Schroedinger identifies new CDC7 inhibitors

April 6, 2022

J2H Biotech identifies new PROTACs for NSCLC

April 5, 2022

Betta Pharmaceuticals presents new CD73 inhibitors

April 5, 2022

Novel carbazole derivatives attenuate mitochondrial function in models of lung adenocarcinoma

April 5, 2022

Shanghai Litedd presents new RET inhibitors

April 4, 2022

New Mat2A inhibitors synthesized by ScinnoHub Pharmaceutical

April 4, 2022

Shanghai Haiju Biotechnology divulges new platinum complexes for cancer

April 4, 2022

New hederagenin derivatives display multidrug resistance reversal in tumors

April 4, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...